NCT01273597 · REGISTRY CONDITION SEARCH

Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: Not reported
Status at capture: COMPLETED
Registry last update: 2013-01-18

This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands. Participants will be followed for 6 months. Data will be collected from participants initiated on Zemplar therapy according to standard of care. The time to achieving the maintenance dose of Zemplar (paricalcitol injection), the proportion of participants achieving target parathyroid hormone levels, and prevalence of elevated serum calcium and phosphate levels will be evaluated.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Time (in Weeks) From Treatment Initiation to Achieving Maintenance Dose of Zemplar (Paricalcitol Injection)

→

outcome · POSTED

Number of Participants Achieving Target Intact Parathyroid Hormone (iPTH) Levels at Month 6

→

outcome · POSTED

Country-Specific Data on the Usage of Medication Affecting Calcium (Ca) Balance

→

outcome · POSTED

Country-Specific Data on the Usage of Medication Affecting Phosphorus (P) Balance

→

outcome · POSTED

Country-Specific Data on the Usage of Medication Affecting Secondary Hyperparathyroidism

→

outcome · POSTED

Number of Participants With Hypercalcaemia During Preceding 6 Months of Conventional Vitamin D Therapy

→

outcome · POSTED

Number of Participants With Hypercalcaemia During 6 Months of Selective Vitamin D Receptor Activator (Paricalcitol) Treatment

→

outcome · POSTED

Number of Participants With Hyperphosphataemia During Preceding Conventional Vitamin D Therapy

→

outcome · POSTED

Number of Participants With Hyperphosphataemia During 6 Months of Selective Vitamin D Receptor Activator (Paricalcitol) Treatment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: Based on the current Hungarian Summary of Product Characteristics for Zemplar (paricalcitol injection), the patient is entitled to treatment with paricalcitol injection and: 1. ≥ 18 years of age, 2. Willing to sign the patient information and informed consent form, 3. Chronic kidney disease (CKD) stage 5 patient receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT), whose intact parathyroid hormone (iPTH) level is: * between 500-800 pg/mL with at least two abruption of conventional vitamin D therapy due to elevated serum calcium level (i.e. \> 2.4 mmol/L) in the medical history, or * higher than 800 pg/mL and parathyroidectomy is contraindicated. 4. The patient is planned to receive paricalcitol treatment independently from his/her participation in this study. Exclusion Criteria: Patients cannot be enrolled in the study if any of the following exclusion criteria apply: 1. The patient is already treated with Zemplar (paricalcitol injection), 2. Any contraindication exists as stated in the current Hungarian Summary of Product Characteristics for Zemplar (paricalcitol injection), 3. Patients who decline to participate in the study or decline to sign the patient information/informed consent form.
healthy Volunteers: false
minimum Age: 18 Years
sampling Method: NON_PROBABILITY_SAMPLE
sex: ALL
std Ages: ADULT
OLDER_ADULT
study Population: Stage 5 chronic kidney disease patients treated in haemodialysis centers in Hungary

Treatment arms and interventions

arm Groups

description
Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
label
End-stage kidney disease with secondary hyperparathyroidism

Study design

observational Model: COHORT
time Perspective: PROSPECTIVE

Enrollment

count: 60
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Maintenance dose is defined as weekly dose of paricalcitol that results in at least 2 consecutive intact parathyroid hormone (iPTH) values within the target therapeutic range of 150 - 300 pg/mL, corresponding to 15.9 - 31.8 pmol/L.
measure
Time (in Weeks) From Treatment Initiation to Achieving Maintenance Dose of Zemplar (Paricalcitol Injection)
time Frame
6 months

secondary Outcomes

description
Target intact parathyroid hormone (iPTH) values were within the target therapeutic range of 150 - 300 pg/mL, corresponding to 15.9 - 31.8 pmol/L.
measure
Number of Participants Achieving Target Intact Parathyroid Hormone (iPTH) Levels at Month 6
time Frame
6 months
description
If available, data on vitamin D treatment (those who received vitamin D supplement products from Anatomical Therapeutic Chemical \[ATC\] group A11CC \[vitamin D and analogues\]) in the 6 months leading up to paricalcitol treatment and during 6 months of paricalcitol treatment were also collected.
measure
Country-Specific Data on the Usage of Medication Affecting Calcium (Ca) Balance
time Frame
6 months prior to start of study through 6 months of treatment
description
If available, data on the use of phosphate binders (those who received calcium-based phosphate binders or sevelamer/lanthanum) in the 6 months leading up to paricalcitol treatment and during 6 months of paricalcitol treatment were also collected.
measure
Country-Specific Data on the Usage of Medication Affecting Phosphorus (P) Balance
time Frame
6 months prior to start of study through 6 months of treatment
description
If available, data on the use of medication affecting secondary hyperparathyroidism (those who received calcimimetics and calcium supplementation) in the 6 months leading up to paricalcitol treatment and during 6 months of paricalcitol treatment were also collected.
measure
Country-Specific Data on the Usage of Medication Affecting Secondary Hyperparathyroidism
time Frame
6 months prior to start of study through 6 months of treatment
description
Hypercalcaemia (serum calcium \> 2.6 mmol/L) among participants during the preceding 6 months of conventional vitamin D therapy was derived from retrospective data collection in case report form, reported at baseline. Conventional vitamin D therapy included vitamin D supplement products from ATC group A11CC (vitamin D and analogues).
measure
Number of Participants With Hypercalcaemia During Preceding 6 Months of Conventional Vitamin D Therapy
time Frame
6 months prior to start of study through baseline
description
Hypercalcaemia (serum calcium \> 2.6 mmol/L), based on laboratory data, was collected during the observed 6 months treatment with Zemplar (paricalcitol injection).
measure
Number of Participants With Hypercalcaemia During 6 Months of Selective Vitamin D Receptor Activator (Paricalcitol) Treatment
time Frame
6 months
description
Hyperphosphataemia (serum phosphorus \>1.78 mmol/L) among participants during the preceding 6 months of conventional vitamin D therapy was derived from retrospective data collection in case report form, reported at baseline. Conventional vitamin D therapy included vitamin D supplement products from ATC group A11CC (vitamin D and analogues).
measure
Number of Participants With Hyperphosphataemia During Preceding Conventional Vitamin D Therapy
time Frame
6 months prior to start of study through baseline
description
Hyperphosphataemia (serum phosphorus \> 1.78 mmol/L), based on laboratory data, was collected during the observed 6 months treatment with Zemplar (paricalcitol injection).
measure
Number of Participants With Hyperphosphataemia During 6 Months of Selective Vitamin D Receptor Activator (Paricalcitol) Treatment
time Frame
6 months

Full study description

brief Summary: This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands. Participants will be followed for 6 months. Data will be collected from participants initiated on Zemplar therapy according to standard of care. The time to achieving the maintenance dose of Zemplar (paricalcitol injection), the proportion of participants achieving target parathyroid hormone levels, and prevalence of elevated serum calcium and phosphate levels will be evaluated.
detailed Description: Prospective data collection started at initial dosing with Zemplar (paricalcitol injection) and ended up to 6 months later. If available, retrospective data on vitamin D treatment as well as on the incidence of hypercalcaemia and hyperphosphataemia in the 6 months leading up to paricalcitol treatment were also collected. Eight visits were planned for documentation of prospective data. In accordance with the non-interventional character of the study, only diagnostic and monitoring procedures were applied which are part of the routine medical care of secondary hyperparathyroidism.

Source references